Abstract
Purpose
To evaluate the effect of intravitreal triamcinolone in eyes with diabetic macular oedema that had no previous laser treatment.
Methods
In all, 12 eyes of 12 patients with diabetic retinopathy, aged 47–70 years (mean 59.2), made up the study. All the eyes had persistent diabetic macular oedema despite having received medical treatment for at least 3 months. In this consecutive case series, none of the eyes received previous laser photocoagulation. Intravitreal injection of 0.1 ml (4 mg) triamcinolone acetonide was offered to treat macular oedema. The visual and anatomic responses were observed as well as complications related to the injection procedure and corticosteroid medication.
Results
The follow-up period was between 6 and 10 months (mean 7.9 months) and all eyes completed 6 months of follow-up. Macular oedema was documented for an average of 3.5 months (ranged 3–5 months) before intravitreal corticosteroid injection. Baseline mean central macular thickness was 448.6 μm. At 1 month follow-up, a reduction in mean central macular thickness of 40.8% from 448.6 μm to 265.4 μm was obtained. At 3 and 6 months follow-up, mean central macular thicknesses, were 310 μm and 294.5 μm, respectively. No eyes lost vision at 1 month and 10 eyes (83.2%) showed improvement. At 3 months, no eyes lost vision from baseline and 8 eyes (66.6%) showed improvement. At 6 months, again no eyes lost vision from baseline and 10 eyes (83.2%) maintained improved visual acuity.
Conclusions
Intravitreal triamcinolone is a promising therapeutic method in eyes with diabetic macular oedema without previous application of laser treatment. Further study with longer follow-up and large series is warranted to assess the long-term efficacy and safety and the need for retreatment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Klein R, Klein BE, Moss SE, David MD, De Mets DL . The Wisconsin Epidemiologic study of Diabetic Retinopathy IV. Diabetic macular oedema. Ophthalmology 1984; 91: 1464–1474.
Photocoagulation for diabetic macular oedema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985; 103: 1796–1806.
Blankenship GW . Diabetic macular oedema and argon laser photocoagulation. A prospective randomized study. Ophthalmology 1979; 86: 69–75.
McDonald HR, Schatz H . Grid photocoagulation of diffuse macular oedema. Retina 1985; 5: 65–72.
Olk RJ . Modified grid argon (blue-green) laser photocoagulation for diffuse macular oedema. Ophthalmology 1986; 93: 938–948.
Schatz H, Maderia D, Johnson RN . Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular oedema. Arch Ophthalmol 1991; 109: 1549–1551.
Harbour JW, Smiddy WE, Flynn Jr HW, Rubsamen PE . Vitrectomy for diabetic macular oedema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996; 121: 405–413.
Ikeda T, Sato S, Katano T, Hayashi Y . Vitrectomy for cystoid macular ooedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol 1999; 83: 12–14.
Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ et al. Vitrectomy for diffuse diabetic macular oedema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000; 130: 178–186.
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002; 109: 920–927.
Jonas JB, Hayler JK, Panda-Jonas S . Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84: 1064–1067.
Danis RP, Bingaman DP, Yang Y, Ladd B . Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099–2104.
Danis RP, Ciulla TA, Pratt LM, Anliker W . Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244–250.
Jonas JB, Söfker A . Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular oedema. Am J Ophthalmol 2001; 132: 425–427.
Degenring RF, Jonas JB . Intravitreal injection of triamcinolone acetonide as a treatment for chronic uveitis. Br J Ophthalmol 2003; 87: 361.
Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudic A . Intravitreal triamcinolone for refractory pseudofakic macular oedema. Am J Ophthalmol 2003; 135: 246–249.
Conway MD, Canakis C, Livir-Rallatos C, Peyman GA . Intravitreal triamcinolone acetonide for refractory chronic pseudofakik cystoid macular oedema. J Cataract Refract Surg 2003; 29: 27–33.
Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E . Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002; 86: 247–248.
Jonas JB, Kreissig I, Degenring RF . Intravitreal triamcinolone acetonide as a treatment of macular oedema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 782–783.
Shatz H, Patz A . Cystoid maculopathy in diabetics. Arch Ophthalmol 1976; 94: 761–768.
Krupin T, Waltman SR, Szewczyk P et al. Fluorometric studies on the blood-retinal barrier in experimental animals. Arch Ophthalmol 1982; 100: 631–634.
Kimber WM, Nichols CW, Grimes PA, Winegrad AI, Laties AM . A permeability defect of the retinal pigment epithelium: occurence in early streptozocin diabetes. Arch Ophthalmol 1980; 98: 725–728.
Schepens CL, Avila MP, Jalkh AE, Trempe CL . Role of the vitreous in cystoid macular oedema. Surv Ophthalmol 1984; 28: 499–504.
Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW et al. The role of the vitreous in diabetic macular oedema. Ophthalmology 1988; 95: 1335–1339.
Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr . Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155–1159.
Jonas JB, Kreissig I, Sofker A, Degnring RF . Intravitreal injection of triamcinolone for diffuse diabetic macular oedema. Arch Ophthalmol 2003; 121: 57–61.
Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular oedema Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19. Arch Ophthalmol 1995; 113: 1144–1155.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have no proprietary interest in the material used in this study.
Rights and permissions
About this article
Cite this article
Karacorlu, M., Ozdemir, H., Karacorlu, S. et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 19, 382–386 (2005). https://doi.org/10.1038/sj.eye.6701512
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701512
Keywords
This article is cited by
-
Intravitreal triamcinolone versus laser photocoagulation as a primary treatment for diabetic macular oedema - a comparative pilot study
BMC Ophthalmology (2011)
-
Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells
Graefe's Archive for Clinical and Experimental Ophthalmology (2009)
-
Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases
Eye (2008)
-
Reply to Dweck et al
Eye (2007)
-
Intravitreal triamcinolone as a primary therapy in diabetic macular oedema
Eye (2006)
